ADMS News and Press, Adamas Pharmaceuticals Inc. From 03/29/21

Disclosing new data from two pivotal, Phase 3 clinical studies, Adamas Pharmaceuticals ([[ADMS]] -5.1%) said that its FDA approved therapy Gocovri (amantadine) to treat dyskinesia in Parkinson’s disease demonstrated an additional 2.9 hours ON time without dyskinesia in PD patients...

-- Patients enrolled in the pivotal trials increased daily ON time without dyskinesia by 2.9 hours with GOCOVRI compared to placebo, through the reduction of both OFF time and dyskinesia - -- GOCOVRI is the first and only therapy for the treatment of OFF and/or dyskinesia for ...

Hall of Fame Resort & Entertainment Company (HOFV) +71% after NFT deal.Dolphin Entertainment (DLPN) +66% after NFT deal.Alithya Group (ALYA) +52% on acquisition of R3D ConseilColor Star Technology (CSCW) +41%.Aptose Biosciences (APTO) +39% on Q4 results.Cinedigm C...

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the closing of its previously announced underwritten public offering of 12,500,000 share...

The following slide deck was published by Adamas Pharmaceuticals, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Adamas Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call Presentation

Adamas Pharmaceuticals (ADMS) -7% premarket on pricing public offering of 12.5M common shares at $4.40/share, for gross proceeds of $55M.Underwriters' over-allotment is an additional 1.875M shares.Offering is expected to close on March 1. For further details see: Adamas Pharmaceuti...

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the pricing of its underwritten public offering of 12,500,000 shares of its common stock...

Adamas Pharmaceuticals (ADMS) announces that it has commenced an underwritten public offering.The company intends to grant the underwriters a 30-day option to purchase up to an aggregate of an additional 15% of shares.SVB Leerink and William Blair are acting as joint bookrunning man...

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that it has commenced an underwritten public offering of its common stock. All shares of...

Adamas Pharmaceuticals, Inc. (ADMS) Q4 2020 Earnings Conference Call February 23, 2021 4:30 PM ET Company Participants Peter Vozzo – Investor Relations Representative Neil McFarlane – Chief Executive Officer Vijay Shreedhar – Chief Commercial Officer Chris Prentiss ȁ...